December 20, 2019 / 1:13 PM / a month ago

Stealth BioTherapeutics' neuromuscular disorder drug fails late-stage study

Dec 20 (Reuters) - Stealth BioTherapeutics Corp said on Friday its drug to treat neuromuscular diseases failed to meet the main goals of a late-stage trial.

The trial was testing the drug, elamipretide, to treat patients with primary mitochondrial myopathy, but failed to help patients walk better and reduce fatigue, the company said. (reut.rs/3918ob9) (Reporting by Trisha Roy in Bengaluru; Editing by Shounak Dasgupta)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below